The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials

OBJECTIVES: The objective of this systematic review was to provide an overview of current developments and potentially available therapeutic options for spondyloarthritis (SpA) in the coming years. METHODS: We conducted a systematic review of 17 national and international clinical trial databases fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Denis, Agathe, Sztejkowski, Cédric, Arnaud, Laurent, Becker, Guillaume, Felten, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387652/
https://www.ncbi.nlm.nih.gov/pubmed/37507210
http://dx.doi.org/10.1136/rmdopen-2023-003279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387652/
https://www.ncbi.nlm.nih.gov/pubmed/37507210
http://dx.doi.org/10.1136/rmdopen-2023-003279

Ejemplares similares